• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$39.87 -$0.04 (-0.10%)

REAL-TIME: Last trade at

Cubist Pharmaceuticals, Inc.

NASDAQ:CBST

Why Buying 'Market Outperform' Zalicus At A Discount Is Savvy

Could The Small Cap Healthcare ETF Be A Great Pick? - ETF News And Commentary

Loss at Optimer in 1Q - Analyst Blog

Alnylam Narrows Loss - Analyst Blog

Cubist Beats, Ups View - Analyst Blog

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Optimer Pharma Evenly Poised - Analyst Blog

With Revenue Decimated, Is ViroPharma a Buy?

ViroPharma Drops on FTC Probe, Generic Drug Rival

2 Positive Signs for Cubist

Top Analyst Upgrades & Downgrades (AET, MO, CVH, CBST, DFS, EXM, HFC, MWW, RAI, XLNX, ZNGA)

Revenues Rise at Optimer Pharma - Analyst Blog

Tranzyme Investors: Why Shares Just Got Halved

Alnylam Delivers In-Line Numbers - Analyst Blog

Alnylam Pharmaceuticals Shares Dropped: What You Need to Know

US STOCK FUTURES: HOT STOCKS TO WATCH

US STOCK FUTURES: HOT STOCKS TO WATCH

Cubicin Drives Cubist Pharma - Analyst Blog

The Gory Details of Cubist Pharmaceuticals' Earnings Miss

Earnings Preview: Cubist Pharma - Analyst Blog

Optimer Buoyant on Difficid Sales - Analyst Blog

Cubist's Preliminary Sales Impress - Analyst Blog

Cubist Pharma 4Q Revenue Tops Views; Cubicin Sales Up 25%

Trius Therapeutics Predicted to Rise on Rival to Pfizer Antibiotic

The 2 Best-Performing Sectors Over the Last Decade

Pipeline Progress at Cubist Pharma - Analyst Blog

Optimer's Dificlir Cleared in EU - Analyst Blog

Cubist Pharma Buys Adolor - Analyst Blog

Is Pharmacyclics the Perfect Stock?

Still Bullish on Alnylam - Analyst Blog

Alnylam Completes Trial Enrollment - Analyst Blog

Alnylam Reveals ALNTTR01 Trial Data - Analyst Blog

Cubist Squares Well With These 2 Metrics

The Highest-Rated Biopharma Stocks

Make Money in Profitable Small Caps the Easy Way

Don't Get Too Worked Up Over ViroPharma's Latest Numbers

Momentum Ideas: Top 7 Rallies to Keep on Your Radar

Is ViroPharma's Growth for Real?

Upgrades & Downgrades: Sun Sets on First Solar

Cubist Pharma Strikes Deal to Buy Adolor for up to $415M

See More Articles...